Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

448 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hydrogen sulfide as an anti-calcification stratagem in human aortic valve: Altered biogenesis and mitochondrial metabolism of H2S lead to H2S deficiency in calcific aortic valve disease.
Combi Z, Potor L, Nagy P, Sikura KÉ, Ditrói T, Jurányi EP, Galambos K, Szerafin T, Gergely P, Whiteman M, Torregrossa R, Ding Y, Beke L, Hendrik Z, Méhes G, Balla G, Balla J. Combi Z, et al. Among authors: gergely p. Redox Biol. 2023 Apr;60:102629. doi: 10.1016/j.redox.2023.102629. Epub 2023 Feb 8. Redox Biol. 2023. PMID: 36780769 Free PMC article.
Lethal threat in the use of glass doors at home: A case report.
Halasi BD, Borsay BÁ, Pórszász RK, Gergely PA. Halasi BD, et al. Among authors: gergely pa. Leg Med (Tokyo). 2024 Feb;66:102365. doi: 10.1016/j.legalmed.2023.102365. Epub 2023 Nov 24. Leg Med (Tokyo). 2024. PMID: 38041907
Case Report: A Sudden Thyroid-Related Death of a 15-Year-Old Girl.
Rácz K, Simon G, Kurucz A, Harsányi GT, Török M, Herczeg LT, Gergely PA. Rácz K, et al. Among authors: gergely pa. Diagnostics (Basel). 2024 Apr 26;14(9):905. doi: 10.3390/diagnostics14090905. Diagnostics (Basel). 2024. PMID: 38732319 Free PMC article.
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
GomezMancilla B, Meriggioli MN, Genge A, Roubenoff R, Espié P, Dupuy C, Hartmann N, Pezous N, Kinhikar A, Tichy M, Dionne A, Vissing J, Andersen H, Schoser B, Meisel A, Jordan B, Devlikamova F, Poverennova I, Stuchevskaya F, Lin TS, Rush JS, Gergely P. GomezMancilla B, et al. Among authors: gergely p. J Clin Neurosci. 2024 Jan;119:76-84. doi: 10.1016/j.jocn.2023.11.013. Epub 2023 Nov 20. J Clin Neurosci. 2024. PMID: 37988976 Clinical Trial.
Efficacy and safety of remibrutinib, a selective potent oral BTK inhibitor, in Sjögren's syndrome: results from a randomised, double-blind, placebo-controlled phase 2 trial.
Dörner T, Kaul M, Szántó A, Tseng JC, Papas AS, Pylvaenaeinen I, Hanser M, Abdallah N, Grioni A, Santos Da Costa A, Ferrero E, Gergely P, Hillenbrand R, Avrameas A, Cenni B, Siegel RM. Dörner T, et al. Among authors: gergely p. Ann Rheum Dis. 2024 Feb 15;83(3):360-371. doi: 10.1136/ard-2023-224691. Ann Rheum Dis. 2024. PMID: 37932009 Free PMC article. Clinical Trial.
First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of MHV370, a Dual Inhibitor of Toll-Like Receptors 7 and 8, in Healthy Adults.
Shisha T, Posch MG, Lehmann J, Feifel R, Junt T, Hawtin S, Schuemann J, Avrameas A, Danekula R, Misiolek P, Siegel R, Gergely P. Shisha T, et al. Among authors: gergely p. Eur J Drug Metab Pharmacokinet. 2023 Sep;48(5):553-566. doi: 10.1007/s13318-023-00847-3. Epub 2023 Aug 2. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37532923 Free PMC article. Clinical Trial.
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
Hawtin S, André C, Collignon-Zipfel G, Appenzeller S, Bannert B, Baumgartner L, Beck D, Betschart C, Boulay T, Brunner HI, Ceci M, Deane J, Feifel R, Ferrero E, Kyburz D, Lafossas F, Loetscher P, Merz-Stoeckle C, Michellys P, Nuesslein-Hildesheim B, Raulf F, Rush JS, Ruzzante G, Stein T, Zaharevitz S, Wieczorek G, Siegel R, Gergely P, Shisha T, Junt T. Hawtin S, et al. Among authors: gergely p. Cell Rep Med. 2023 May 16;4(5):101036. doi: 10.1016/j.xcrm.2023.101036. Cell Rep Med. 2023. PMID: 37196635 Free PMC article.
Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
Dertschnig S, Gergely P, Finke J, Schanz U, Holler E, Holtick U, Socié G, Medinger M, Passweg J, Teshima T, Stylianou C, Oehen S, Heim D, Bucher C. Dertschnig S, et al. Among authors: gergely p. Transplant Cell Ther. 2023 Jan;29(1):41.e1-41.e9. doi: 10.1016/j.jtct.2022.10.029. Epub 2022 Nov 4. Transplant Cell Ther. 2023. PMID: 36343893 Free article. Clinical Trial.
448 results